Clinical Trials Browser

Not yet recruiting × OTHER × Waldenstrom Macroglobulinemia × Clear all

Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Phase 4 Not yet recruiting

80 enrolled

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

NCT07420959 2026-02-19

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

Phase 1/2 Not yet recruiting

38 enrolled

Lymphoid

Waldenstrom Macroglobulinemia

NCT07259122 2025-12-02

ZBR in WM

Phase 2 Not yet recruiting

43 enrolled

Lymphoid

Waldenstrom Macroglobulinemia

NCT06547866 2025-11-26

WAZABI

Phase 2 Not yet recruiting

102 enrolled

Lymphoid

Waldenstrom Macroglobulinemia

NCT07169565 2025-09-11

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Phase 1 Not yet recruiting

21 enrolled

Lymphoid

Waldenstrom Macroglobulinemia

NCT06942507 2025-04-30

BRZ-WM

Phase NA Not yet recruiting

104 enrolled

Lymphoid

Waldenstrom Macroglobulinemia

NCT04702932 2021-01-11

GEN-HEMO-INF

Not yet recruiting

30 enrolled

LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Clinical Trials

BLOOD-dose

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

ZBR in WM

WAZABI

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

BRZ-WM

GEN-HEMO-INF